Tanios S. Bekaii-Saab, MD, FACP of Mayo Clinic explains whether or not there is a standard second line treatment for patients with hepatocellular carcinoma (HCC) and who failed first line therapy. He argues that Regorafenib should be used for second line therapy. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.
Is There a Standard Second Line Therapy for HCC?
